Ontology highlight
ABSTRACT: Objective
To quantify more reliably the benefits and risks of monoamine oxidase type B inhibitors (MAOBIs) in early Parkinson's disease.Data sources
Searches of the Cochrane Library, Medline, Embase, PubMed, and Web of Science for years 1966-2003, plus major journals in the field, abstract books, and proceedings of meetings, for randomised trials comparing MAOBIs with placebo or levodopa.Data extraction
Available data on mortality, motor complications, side effects, treatment compliance, and clinician rated disability (for example, unified Parkinson's disease rating scale) were extracted from 17 trials and combined using standard meta-analytic methods.Results
No significant difference in mortality existed between patients on MAOBIs and control patients (odds
SUBMITTER: Ives NJ
PROVIDER: S-EPMC516655 | biostudies-literature | 2004 Sep
REPOSITORIES: biostudies-literature